IO Biotech Ownership

IOBT Stock  USD 0.92  0.04  4.55%   
IO Biotech secures a total of 65.88 Million outstanding shares. Over half of IO Biotech's outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Dividend Paid And Capex Coverage Ratio is likely to drop to -209.88 in 2025. Common Stock Shares Outstanding is likely to drop to about 34.9 M in 2025. Net Loss is likely to drop to about (67.5 M) in 2025.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IO Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy IOBT Stock please use our How to Invest in IO Biotech guide.

IOBT Stock Ownership Analysis

About 67.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.79. Some equities with similar Price to Book (P/B) outperform the market in the long run. IO Biotech recorded a loss per share of 1.29. The entity had not issued any dividends in recent years. IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company was incorporated in 2014 and is based in Copenhagen, Denmark. Io Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people. To learn more about IO Biotech call the company at 45 70 70 29 80 or check out https://www.iobiotech.com.
Besides selling stocks to institutional investors, IO Biotech also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different IO Biotech's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align IO Biotech's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

IO Biotech Quarterly Liabilities And Stockholders Equity

89.94 Million

Less than 1% of IO Biotech are currently held by insiders. Unlike IO Biotech's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against IO Biotech's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of IO Biotech's insider trades

IOBT Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as IO Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading IO Biotech backward and forwards among themselves. IO Biotech's institutional investor refers to the entity that pools money to purchase IO Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Bridgeway Capital Management, Llc2024-12-31
174 K
Renaissance Technologies Corp2024-12-31
118.8 K
Sectoral Asset Management Inc2024-12-31
75 K
Royal Bank Of Canada2024-12-31
60 K
Ubs Group Ag2024-12-31
47 K
Geode Capital Management, Llc2024-12-31
33.3 K
Vontobel Holding Ltd.2024-12-31
32.7 K
Xtx Topco Ltd2024-12-31
28 K
Pks Advisory Services, Llc2024-12-31
16 K
Vivo Capital, Llc2024-12-31
6.2 M
Novo A/s2024-12-31
3.4 M
Note, although IO Biotech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

IO Biotech Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IO Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on IO Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases IO Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

IO Biotech Outstanding Bonds

IO Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. IO Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most IOBT bonds can be classified according to their maturity, which is the date when IO Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for IOBT Stock Analysis

When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.